Pfizer
NEWS
Current Chief Executive Officer Albert Bourla will succeed Read as chairman on Jan. 1, 2020 and will continue to serve as CEO.
Pfizer announced positive top-line results from the first trial in May.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Nearly one year after it was launched by Pfizer and Bain Capital, Cerevel Therapeutics has tapped industry veteran Tony Coles as its chief executive officer.
“This investment will further strengthen Pfizer’s leadership in gene therapy manufacturing technology,” stated Mike McDermott, president, Pfizer Global Supply.
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
The goal of the trial was to evaluate the efficacy and safety of the drug in patients six years of age and older with SCD who were hospitalized for a vaso-occlusive crisis and required treatments with intravenous opioids.
There were a number of major companies reporting their second-quarter financials for the year. Here’s a look at five of the bigger announcements this week.
JOBS
IN THE PRESS